Sun Pharmaceutical Industries is currently trading at Rs. 429.30, up by 4.55 points or 1.07% from its previous closing of Rs. 424.75 on the BSE.
The scrip opened at Rs. 428.95 and has touched a high and low of Rs. 434.40 and Rs. 425.40 respectively. So far 287502 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 678.80 on 06-Sep-2018 and a 52 week low of Rs. 391.10 on 11-Dec-2018.
Last one week high and low of the scrip stood at Rs. 434.90 and Rs. 419.25 respectively. The current market cap of the company is Rs. 103039.15 crore.
The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 33.31% and 12.31% respectively.
Sun Pharmaceutical Industries’ wholly owned subsidiary has received approval from US Food and Drug Administration (USFDA) for the New Drug Application (NDA), for Elepsia XR 1000 mg (levetiracetam 1000 mg) and Elepsia XR 1500 mg (levetiracetam 1500 mg). This product was filed from SPIL’s Halol facility in the state of Gujarat.
The company’s wholly owned subsidiary had in-licensed ELEPSIA XR from Sun Pharma Advanced Research Company (SPARC) in July 2016.
Sun Pharmaceutical Industries (SPIL) is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: